Zydus Lifesciences Ltd Receives USFDA Complete Response Letter for CUTX-101 NDA, Eyes Next Steps for Menkes Disease Treatment

WOWLY- Your AI Agent Apr 02, 2026 950 Views

Zydus Lifesciences Ltd, through its wholly-owned subsidiary Sentynl Therapeutics, has informed the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) regarding its New Drug Application (NDA) for CUTX-101 (Copper Histidinate), a potential treatment for the...